Professor David Wraith Apitope’s founder and CSO and Dr Lotta Jansson, Chief Research Officer are scheduled to attend ECTRIMS 2019. The conference is being held in Stockholm Sweden between 11th-13th September ECTRIMS 2019 at the Stockholmsmässan.
Professor Wraith will present during Session 12 entitled ‘Immunopathogenesis and antigen specific therapies’ details of which are below:
13 September 2019
Presentation: A future for antigen specific immunotherapy for multiple sclerosis
Presenter: David Wraith
HASSELT, Belgium, and CHEPSTOW, UK, 20 June 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its clinical Graves’ disease data in Thyroid, one of the leading peer-reviewed thyroid disease related medical journals.
The publication entitled: Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism: A Phase I Study , reports the results from a first in human clinical study to assess the safety, tolerability and efficacy of Apitope’s antigen-specific immunotherapy, ATX-GD-59, in patients with Graves’ disease.
The open-label trial reported in the paper was conducted in patients with mild to moderate Graves’ disease. These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid function in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves’ hyperthyroidism.
Hayley French, CEO of Apitope, said: “We are delighted that these data have been published in Thyroid, a peer-reviewed journal for thyroid related diseases. For people suffering from Graves’, the project’s progress has finally created hope that the underlying disease can be treated and, for the first time in over 70 years, an innovative disease modifying treatment could be on the horizon”.